InTandem
Commercial- Indications
- Chronic stroke walking deficits
Company intelligence / Profile preview
MedRhythms’ lead digital therapeutic for chronic stroke walking deficits has shown promising early results in increasing patient walking speed after just three sessions. The pivotal trial supporting regulatory approval is ongoing. Additional clinical studies are underway or planned for multiple sclerosis and Parkinson’s disease.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MedRhythms.